Y-Intercept (HK)’s Praxis Precision Medicines PRAX Stock Holding History

Y-Intercept (HK)’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,856	Closed	-$547K	–	1945
2025 Q4	$547K	Sell	1,856 -30,330	-94%	-$5.65M	0.01%	1209
2025 Q3	$1.71M	Buy	+32,186	New	+$1.56M	0.04%	701
2025 Q2	–	Sell	-6,250	Closed	-$237K	–	1936
2025 Q1	$237K	Buy	+6,250	New	+$390K	0.02%	997
2024 Q2	–	Sell	-11,776	Closed	-$719K	–	1804
2024 Q1	$719K	Buy	+11,776	New	+$528K	0.05%	525
2023 Q3	–	Sell	-4,478	Closed	-$77.3K	–	1478
2023 Q2	$77.3K	Buy	+4,478	New	+$68.6K	0.01%	1145
2023 Q1	–	Sell	-924	Closed	-$33K	–	1461
2022 Q4	$33K	Sell	924 -3,643	-80%	-$114K	﹤0.01%	930
2022 Q3	$156K	Buy	+4,567	New	+$228K	0.02%	850

Other funds holding PRAX

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Y-Intercept (HK)'s PRAX Position: Q1 2026 in Review

Y-Intercept (HK) sold out of Praxis Precision Medicines (PRAX) in Q1 2026, closing a stake of 1,856 shares — an estimated $547K sold.

Y-Intercept (HK) first reported a position in PRAX in Q3 2022 and held it in 7 quarters. The position peaked at $1.71M in Q3 2025. 291 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

Y-Intercept (HK) reported no remaining Praxis Precision Medicines position as of Q1 2026 after selling out during the quarter.
Y-Intercept (HK) sold 1,856 Praxis Precision Medicines shares in Q1 2026, an estimated $547K.
Y-Intercept (HK) first reported a position in Praxis Precision Medicines in Q3 2022 and held it in 7 quarters.
Y-Intercept (HK)'s Praxis Precision Medicines position peaked at $1.71M in Q3 2025.
291 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Y-Intercept (HK)'s 13F filing for Q1 2026, filed 27 Apr 2026.